
price data provid thomson reuter
number may add due round
financi rais pt posit myasthenia
continu impress compani clinic progress across
pipelin differenti antibodi rare autoimmun diseas cancer
increas pt chang valuat result primarili
decreas risk-adjust discount rate efgartigimod gener
myasthenia gravi gmg note favor enrol
progress pivot ph adapt studi well evid increas
demand novel therapi indic exhibit recently-report
perform metric alexion op laura chico soliri refractori
achr gmg pt approv note sequenti q/q increas soliris-
treat pt us figur addit note
efgartigimod address broader patient popul soliri less
refractori autoantibodi agnost expect price significantli
lower price point model annual price vs soliri
current valu efgartigimod opportun gmg least
upsid event posit ph readout separ
highlight rest argx pipelin progress expect remain
mileston includ initi ph iv efgartigimod trial immun
thrombocytopenia itp ph initi efgartigimod janssen-partn
cusatuzumab chronic inflammatori demyelin polyneuropathi cidp
acut myeloid leukemia aml respect cta file initi first-in-
human studi healthi volunt ph healthi volunt data
evalu halozym enhanz sc formul efgartigimod
argx also present annual wedbush pacgrow healthcar
confer new york tuesday august regist
ph advanc studi efgartigimod pt immun thrombocytopenia
itp expect start argx provid initi commentari ph
design evalu efgartigimod mg/kg iv addit soc vs
placebo soc treatment period target adult pt
primari itp platelet level stabl soc random double-
blind placebo-control multicent trial primari endpoint studi
proport pt exhibit sustain clinic respons defin
demonstr platelet count least pt visit secondari
endpoint includ measur efficaci safeti toler
incid sever bleed event qol treatment
period pt elig roll one-year open-label extens trial
wedbush secur seek busi compani cover
research report thu investor awar firm may
conflict interest could affect object report investor
consid report singl factor make invest decis
pleas see page report analyst certif import
two program mid-to-l stage clinic develop product llama-deriv antibodi discoveri
platform plu sever valid collabor place see argx current valuat fulli appreci
compani opportun rare autoimmun diseas cancer
efgartigimod cusatuzumab fail
show suffici efficaci target
efgartigimod approv
treat mg itp cidp
develop aml/md
broader expect label
efgartigimod pf
sle cusatuzumab better
expect efficacy/safeti
and/or success
efgartigimod trial initi ph iv itp ph
start ph registration-direct cusatuzumab trial
aml
ph enhanz sc data hv
cta file
sum-of-part base multipl ww efgartigimod
sale mg/itp/pv/cidp discount
plu mult us/ex-u cusatuzumab sales/
royalti aml discount
continu clinic progress efgartigimod across
indic valuabl program argx
pipelin opinion
posit clinic advanc efgartigimod
cusatuzumab program significantli increas
awar confid compani
argen-x develop antibodi therapeut
treatment cancer autoimmun diseas use
proprietari simpl platform fc-optim
creat bluematrix
egartigimod pemphigu vulgari pv next data updat expect argx
continu enrol pt third cohort ph open-label trial
evalu clinic remiss diseas control rate among pt pt number
small prior pv updat encourag rapid diseas
control seen evalu pt pt within wk fourth within wk well
evid clear pd effect mean decreas pathogen igg favor
efgartigimod chronic inflammatori demyelin polyneuropathi cidp ph
initi expect argx remain track initi ph trial
efgartigimod cidp see strong biolog clinic rational
clear parallel gmg look forward addit detail efgartigimod
develop plan indic expect kol event fall
enhanc sc efgartigimod formulationph data expect argx halozym
nc recent dose first subject juli ph healthi volunt trial
evalu halozym proprietari enhanz sc drug deliveri technolog safeti
pk/pd bioavail follow data updat argx like discuss bridg
strategi iv formul regul current envis potenti
commerci strategi involv sc formul argx either
stand-alone mainten product iv formul would primarili use
initi load induct dose potenti rescu set believ
pursu three product formul compani well-posit offer
appropri one differ patient popul
cuzatuzumab acut myeloid leukemia aml ph trial
expect start guidanc remain initi ph
combin azacitidin newly-diagnos aml pt unfit intens
evalu mab
multifoc motor neuropathi mmn cta file expect
discuss detail day see prior note mab
sweep mechan target complement compon strong
scientif rational number sever complement-medi autoimmun diseas
within neuromuscular space mmn name first indic argx
exercis second option investig enhanz sc technolog
antibodi
argx report net loss ep
estim net loss period due primarili lower-than-expect
recognit collabor revenu vs estim greater-than-
expect opex vs estim note increas opex mainli
result increas headcount clinic expens ph adapt studi continu
enrol compani prepar initi sever new efgartigimod studi fx effect
also neg effect net earn loss quarter vs prior period
gain argx finish quarter cash equival posit includ
restrict cash non-curr invest provid suffici runway
reiter rate outperform increas pt sum-
of-part valuat base multipl efgartigimod sale mg discount back
itp discount back pv discount back plu
multipl argx share us cusatuzumab sale multipl ex-u royalti
discount back current valu wholly-own preclin asset
partnered-asset also argx-
due early-stag develop chang valuat result primarili
decreas risk-adjust discount rate efgartigimod gener myasthenia gravi
note favor enrol progress pivot ph adapt studi
well evid increas demand novel therapi indic exhibit
recently-report perform metric alexion op laura chico soliri
updat valuat tabl financi model
figur argx wholly-own co-develop pipelin overview
clinic programindicationmarketaddress populationpeak penetr annual price/ patientlaunch datevalu yeareconomicsdiscount ratemultiplevaluationp share valueu valuat myeloid leukemia aml myasthenia gravi mg chronic inflammatori demyelin polyneuropathi cidp immun thrombocytopenia itppemphigu vulgari product revenu revenu revenu expens sale oper expens incom loss interest incom expens non-op incom expens incom tax incom tax incom loss ep ep share share burn balanc thousand except per share data valu eur valuat
sum-of-part base multipl ww efgartigimod sale mg/itp/pv/cidp discount plu mult
us/ex-u cusatuzumab sales/royalti aml discount
risk attain price rate
risk attain price target rate includ clinic regulatori commerci failur efgartigimod
david nierengarten jeffrey la rosa matthew barcu certifi view express report accur reflect
person opinion directli indirectli receiv compens payment connect
specif recommend view contain report
outperform expect total return stock outperform rel median total return analyst analyst
team coverag univers next month
neutral expect total return stock perform in-lin median total return analyst analyst team
coverag univers next month
under-perform expect total return stock under-perform rel median total return analyst
analyst team coverag univers next month
invest rate base expect perform stock base anticip total return price target rel
stock analyst coverag univers analyst team coverag
august
august
distribut rate requir finra rule howev ws stock rate outperform neutral under-perform
close conform buy hold sell respect pleas note howev definit ws stock rate
rel basi
analyst respons prepar research report receiv compens base specif invest bank activ
analyst receiv compens base upon variou factor includ ws total revenu portion gener
ws invest bank activ
